Daratumumab for Polyneuropathy Associated With MGUS
Condition(s):Peripheral Neuropathy; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:January 29, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Peripheral Neuropathy; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:January 29, 2024Recruiting
Condition(s):Monoclonal Gammopathy of Undetermined Significance (MGUS); Smoldering Multiple Myeloma (SMM)Last Updated:March 20, 2024Not yet recruiting
Condition(s):Monoclonal Gammopathy of Unknown SignificanceLast Updated:September 2, 2020Unknown status
Condition(s):Neuropathy; Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)Last Updated:September 11, 2018Terminated
Condition(s):Multiple Myeloma; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:January 10, 2024Recruiting
Condition(s):Multiple Myeloma; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:August 1, 2023Recruiting
Condition(s):Monoclonal Gammopathy of Undetermined SignificanceLast Updated:July 19, 2023Active, not recruiting
Condition(s):Smoldering Myeloma; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:March 8, 2021Terminated
Condition(s):Multiple Myeloma; Smoldering Multiple Myeloma; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:August 14, 2017Completed
Condition(s):Monoclonal Gammopathy of Undetermined Significance; Smoldering MyelomaLast Updated:April 15, 2021Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.